Skip to main content
SpringerLink
Log in

Patient with Resistant Hypertension

  • Chapter
  • First Online:
Hypertension and 24-hour Ambulatory Blood Pressure Monitoring

Part of the book series: Practical Case Studies in Hypertension Management ((PCSHM))

  • 775 Accesses

Abstract

A 68-year-old, Caucasian male was referred by his family physician for assessment of uncontrolled arterial hypertension. He is treated with three antihypertensive drugs. 24-h ambulatory blood pressure monitoring (ABPM) was performed, and the final diagnosis was true resistant hypertension.

The definition of resistant hypertension is based on office blood pressure (BP) measurements. ABPM is mandatory in resistant hypertensive patients to define true and white-coat resistant hypertension, as the latter group has a better prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Williams B, Mancia G, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;39(33):3021–104.

    Google Scholar 

  2. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:2199–269.

    Article  Google Scholar 

  3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.

    Article  CAS  Google Scholar 

  4. Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol. 2016;32:603–6.

    Article  Google Scholar 

  5. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902.

    Article  Google Scholar 

  6. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422–8.

    Article  Google Scholar 

  7. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712–8.

    Article  CAS  Google Scholar 

  8. Segura J, Ruilope LM. Resistant hypertension. In: Lerma EV, Rosner MH, Perazella MA, editors. Current diagnosis & treatment: nephrology & hypertension. 2nd ed. New York: McGraw-Hill Education; 2018.

    Google Scholar 

  9. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;5(5):147–52.

    Article  Google Scholar 

  10. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens. 2010;28:2329–35.

    Article  CAS  Google Scholar 

  11. Segura J, Cerezo C, Garcia-Donaire JA, Schmieder RE, Praga M, de la Sierra A, et al. Validation of a therapeutic scheme for the treatment of resistant hypertension. J Am Soc Hypertens. 2011;5:498–504.

    Article  CAS  Google Scholar 

  12. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069–75.

    Article  CAS  Google Scholar 

  13. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit, Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain

    Julian Segura

Authors
  1. Julian Segura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Segura, J. (2019). Patient with Resistant Hypertension. In: Hypertension and 24-hour Ambulatory Blood Pressure Monitoring. Practical Case Studies in Hypertension Management. Springer, Cham. https://doi.org/10.1007/978-3-030-02741-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-02741-4_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-02740-7

  • Online ISBN: 978-3-030-02741-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation